van Staa TP, Card TR, Leufkens HG, Logan RF. 5-aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut. 2005 Jun 30;

Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised, controlled trial, of azathioprine and 5- aminosalicylic acid for treatment of steroid-dependent ulcerative colitis. Gut. 2005 Jun 21;

Katsanos KH, Christodoulou DK, Michael M, Ioachim E, Tsianos GV, Agnantis N, Tsianos EV. Inflammatory bowel disease-related dysplasia and cancer: A referral center study in northwestern Greece. Eur J Intern Med. 2005 Jun;16(3):170-175.

Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JW, Dube R, Cohen A, Steinhart AH, Landau S, Aguzzi RA, Fox IH, Vandervoort MK. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.
N Engl J Med. 2005 Jun 16;352(24):2499-507.

Musch E, Andus T, Kruis W, Raedler A, Spehlmann M, Schreiber S, Krakamp B, Malek M, Malchow H, Zavada F, Engelberg Feurle G. Interferon-beta-1a for the Treatment of Steroid-Refractory Ulcerative Colitis: A Randomized, Double-Blind, Placebo-Controlled Trial.
Clin Gastroenterol Hepatol. 2005 Jun;3(6):581-6.

Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C, Vilien M, Strom M, Danielsson A, Verbaan H, Hellstrom PM, Magnuson A, Curman B. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005 Jun;128(7):1805-11

Rubin DT, Lashner BA. Will a 5-ASA a day keep the cancer (and dysplasia) away? Am J Gastroenterol. 2005 Jun;100(6):1354-6.

Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005 Jun;100(6):1345-53.

Yamamoto T, Umegae S, Kitagawa T, Matsumoto K. Systemic and local cytokine production in quiescent ulcerative colitis and its relationship to future relapse: a prospective pilot study.
Inflamm Bowel Dis. 2005 Jun;11(6):589-96.

Cao Q, Si JM, Gao M, Zhou G, Hu WL, Li JH. Clinical presentation of inflammatory bowel disease: a hospital based retrospective study of 379 patients in eastern China. Chin Med J (Engl). 2005 May 5;118(9):747-52.

Higgins PD, Schwartz M, Mapili J, Krokos I, Leung J, Zimmermann EM. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis.
Gut. 2005 Jun;54(6):782-8.

Aberra FN, Brensinger CM, Bilker WB, Lichtenstein GR, Lewis JD. Antibiotic use and the risk of flare of inflammatory bowel disease.
Clin Gastroenterol Hepatol. 2005 May;3(5):459-65.

Hui T, Landers C, Vasiliauskas E, Abreu M, Dubinsky M, Papadakis KA, Price J, Lin YC, Huiying Y, Targan S, Fleshner P. Serologic responses in indeterminate colitis patients before ileal pouch-anal anastomosis may determine those at risk for continuous pouch inflammation. Dis Colon Rectum. 2005 Jun;48(6):1254-62.

Tahara T, Inoue N, Hisamatsu T, Kashiwagi K, Takaishi H, Kanai T, Watanabe M, Ishii H, Hibi T. Clinical significance of microsatellite instability in the inflamed mucosa for the prediction of colonic neoplasms in patients with ulcerative colitis. J Gastroenterol Hepatol. 2005 May;20(5):710-5.

Chen QK, Yuan SZ, Wen ZF, Zhong YQ, Li CJ, Wu HS, Mai CR, Xie PY, Lu YM, Yu ZL. Characteristics and therapeutic efficacy of sulfasalazine in patients with mildly and moderately active ulcerative colitis. World J Gastroenterol. 2005 Apr 28;11(16):2462-6.

Johnson GJ, Cosnes J, Mansfield JC. Review article: smoking cessation as primary therapy to modify the course of Crohn's disease. Aliment Pharmacol Ther. 2005 Apr 15;21(8):921-31. Review.